Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
2 competitors in Geographic Atrophy Secondary to Age-related Macular Degeneration
View Full LandscapeTarget Indication
Geographic Atrophy Secondary to Age-related Macular Degeneration
Clinical Trial
NCT04770545Last updated: 12/4/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Syfovre
Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
View on EMAAspaveli
Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. Aspaveli is indicated for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated.